All In Biotech

Drug Trial Radar · NCT04009499

A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,131

Actual

Start

Aug 13, 2019

Primary completion

May 26, 2026

Study completion May 26, 2026

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jul 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to assess the long-term safety, long-term efficacy and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA).

Conditions

  • Psoriatic Arthritis

Interventions

  • BimekizumabDrug

    Subjects will receive bimekizumab at pre-specified time-points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) during the studyTime frame: From PA0012 Entry Visit until Safety Follow-Up (up to Week 212)
  2. Incidence of treatment-emergent serious adverse events (SAEs) during the studyTime frame: From PA0012 Entry Visit until Safety Follow-Up (up to Week 212)

Locations

138 sites in 14 countries. Site status is shown where the registry gives one.

  • Pa0012 50017

    Phoenix, Arizona

  • Pa0012 50035

    San Diego, California

  • Pa0012 50033

    Palm Harbor, Florida

  • Pa0012 50037

    Tampa, Florida

  • Pa0012 50039

    Atlanta, Georgia

  • Pa0012 50024

    Boise, Idaho

  • Pa0012 50028

    Lexington, Kentucky

  • Pa0012 50023

    Baton Rouge, Louisiana

  • Pa0012 50015

    Hagerstown, Maryland

  • Pa0012 50047

    Boston, Massachusetts

  • Pa0012 50019

    Lansing, Michigan

  • Pa0012 50016

    St Louis, Missouri

  • Pa0012 50005

    Freehold, New Jersey

  • Pa0012 50029

    Albuquerque, New Mexico

  • Pa0012 50010

    Brooklyn, New York

  • Pa0012 50011

    New York, New York

  • Pa0012 50034

    Rochester, New York

  • Pa0012 50125

    Charlotte, North Carolina

  • Pa0012 50031

    Winston-Salem, North Carolina

  • Pa0012 50040

    Vandalia, Ohio

  • Pa0012 50020

    Duncansville, Pennsylvania

  • Pa0012 50006

    Wyomissing, Pennsylvania

  • Pa0012 50008

    Johnston, Rhode Island

  • Pa0012 50007

    Orangeburg, South Carolina

  • Pa0012 50001

    Jackson, Tennessee

  • Pa0012 50012

    Memphis, Tennessee

  • Pa0012 50002

    Austin, Texas

  • Pa0012 50049

    Corpus Christi, Texas

  • Pa0012 50036

    Mesquite, Texas

  • Pa0012 50009

    Waco, Texas

  • Pa0012 50050

    Beckley, West Virginia

  • Pa0012 30005

    Camberwell, Australia

  • Pa0012 30002

    Clayton, Australia

  • Pa0012 30008

    Hobart, Australia

  • Pa0012 30003

    Maroochydore, Australia

  • Pa0012 30007

    Victoria Park, Australia

  • Pa0012 30006

    Woodville South, Australia

  • Pa0012 40003

    Genk, Belgium

  • Pa0012 40002

    Leuven, Belgium

  • Pa0012 40059

    Mons, Belgium

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.